June 2017 in “Journal of The American Academy of Dermatology” Most men with lichen planopilaris had it confirmed by biopsy and often had thyroid issues, sexual dysfunction, or prostate cancer, hinting at a link with hormonal problems.
November 2013 in “International Journal of Dermatology” New skin lesions on the scrotum or vulva in patients with a history of internal cancer could indicate rare skin metastasis.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.
May 2011 in “Expert Review of Endocrinology & Metabolism” Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.
September 2010 in “European Urology Supplements” PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.
June 2010 in “Journal of Chemical Crystallography” The compound was successfully made and shows potential for treating prostate cancer.
April 2023 in “Cancer research” KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.
May 2007 in “The Journal of Urology” Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
Androgen-modulating drugs do not significantly change the heat sensitivity of prostate cancer cells.
January 2022 in “Skin appendage disorders” Finasteride is effective for male hair loss, but it may cause fertility issues, mental health problems, and rarely, breast growth. Regular health checks can reduce the risk of prostate cancer. Patient understanding and involvement in treatment is important.
January 2016 in “Hair transplant forum international” Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.
June 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Six new risk spots for early hair loss were found, which also link to Parkinson's disease and lower fertility. Two genes, FOXA2 and HDAC4, could be new treatment targets. Hair loss might also be connected to heart disease, metabolic syndrome, and prostate cancer.
20 citations,
May 2011 in “Cancer Biology & Therapy” Finasteride may improve prostate cancer treatment outcomes.
5 citations,
January 2022 in “Clinical cancer investigation journal” Certain Dibenzo derivatives may help treat prostate cancer.
1 citations,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
February 2012 in “Community oncology” Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.
March 2009 in “The Journal of Urology” Low dose finasteride causes only small changes in PSA levels in older men with BPH.
228 citations,
February 2003 in “Urology” Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.
60 citations,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
46 citations,
February 2012 in “Oncology Reports” Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
33 citations,
January 2016 in “Indian Journal of Dermatology, Venereology and Leprology” Taking 1 mg of finasteride daily can increase hair count and improve hair appearance, but it may have side effects on sexual function and a potential risk of prostate cancer. It may not be effective for postmenopausal women unless taken in higher doses.
10 citations,
June 2010 in “Expert Opinion on Drug Metabolism & Toxicology” Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.
6 citations,
January 2020 in “The Aging Male” Testosterone replacement therapy improved blood sugar and fat levels without raising prostate cancer risk in Japanese men with low testosterone.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
24 citations,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
3 citations,
January 2023 in “Clinical cancer investigation journal” Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.
41 citations,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
30 citations,
June 1988 in “Journal of Steroid Biochemistry” Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.
29 citations,
October 1988 in “Journal of Steroid Biochemistry” Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.